In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features.

Ignazia TusaGiulia CheloniMartina PotetiAngela SilvanoAlessandro TubitaZoe LombardiAntonella GozziniRoberto CaporaleBarbara ScappiniPersio Dello SbarbaElisabetta Rovida

Published in: Targeted oncology (2021)

Ponatinib seems to target CML progenitor/stem cells better than imatinib.

Keyphrases

chronic myeloid leukemia
stem cells
cell fate
cell therapy
bone marrow